Skip to main content
Premium Trial:

Request an Annual Quote

Structural Bioinformatics Uses Sequence Data to Generate Lead Molecules


SAN DIEGO, Calif.--Applying its proprietary protein-modeling technology to gene sequence data, Structural Bioinformatics here has developed a number of small-molecule nonpeptide lead molecules in multiple chemical classes that are active against the EPO receptor, the company announced recently. To find leads for a variety of structure-based drug design projects, Structural uses an analysis of target sites on a protein structure together with virtual screening. When no 3-D protein structure is available, analyses are performed on a high-quality protein model based in part on related protein structures and augmented with proprietary loop modeling and other refinements.

Edward Maggio, Structural's CEO, called the new development "another validation of our proprietary protein-modeling approach to drug design that permits rapid generation of novel leads from gene sequence for which no protein crystal structures are available."

Filed under

The Scan

Highly Similar

Researchers have uncovered bat viruses that are highly similar to SARS-CoV-2, according to Nature News.

Gain of Oversight

According to the Wall Street Journal, the Biden Administration is considering greater oversight of gain-of-function research.

Lasker for mRNA Vaccine Work

The Scientist reports that researchers whose work enabled the development of mRNA-based vaccines are among this year's Lasker Award winners

PLOS Papers on Causal Variant Mapping, Ancient Salmonella, ALK Fusion Test for NSCLC

In PLOS this week: MsCAVIAR approach to map causal variants, analysis of ancient Salmonella, and more.